Grace Therapeutics Inc
GRCE
$3.39 -2.31%
Exchange: NASDAQ | Sector: Healthcare | Industry: Biotechnology
Q1 2026
Published: Aug 12, 2025

Earnings Highlights

  • EPS of $-0.21 increased by 38.2% from previous year
  • Net income of -3.36M
  • "Transcript not provided in the data." - N/A
GRCE
Company GRCE

Executive Summary

Grace Therapeutics is reporting its QQ1 2026 results with no revenue yet and a substantive operating loss driven by ongoing R&D and commercialization preparations. The quarter shows an EBITDA of -3.36 million and net income of -3.362 million, translating into an EPS of -0.21 on 15.9 million weighted average shares. With cash and cash equivalents of $20.0 million and a net cash position of -$20.0 million (i.e., net cash), the company maintains a meaningful liquidity runway while continuing to fund its pipeline activities. The balance sheet is heavily weighted by intangible assets and goodwill, reflecting pipeline and potential acquisition-related value, which implies heightened impairment and milestone-risk scrutiny but also potential upside if late-stage program milestones are achieved.

Key Performance Indicators

Operating Income
Increasing
-3.09M
QoQ: 16.58% | YoY: 5.30%
Net Income
Decreasing
-3.36M
QoQ: 19.09% | YoY: -6.19%
EPS
Increasing
-0.21
QoQ: 41.67% | YoY: 38.24%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2026 0.00 -0.06 +0.0% View
Q1 2026 0.00 -0.21 +0.0% View
Q3 2024 0.00 -0.36 +0.0% View
Q2 2024 0.00 -0.30 +0.0% View
Q1 2024 0.00 -0.24 +0.0% View